Thioridazine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318864

CAS#: 50-52-2 (free base)

Description: Thioridazine is a piperidine typical antipsychotic drug belonging to the phenothiazine drug group and was previously widely used in the treatment of schizophrenia and psychosis; the branded product was withdrawn worldwide in 2005 because it caused severe cardiac arrhythmias, however, generic versions are available in the US.

Chemical Structure

img
Thioridazine
CAS# 50-52-2 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 318864
Name: Thioridazine
CAS#: 50-52-2 (free base)
Chemical Formula: C21H26N2S2
Exact Mass: 370.15
Molecular Weight: 370.573
Elemental Analysis: C, 68.07; H, 7.07; N, 7.56; S, 17.30

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 130-61-0 (HCl)   50-52-2 (free base)    

Synonym: Thioridazine; Mellaril; Melleril; Aldazine; Melzine.

IUPAC/Chemical Name: 10-(2-(1-methylpiperidin-2-yl)ethyl)-2-(methylthio)-10H-phenothiazine

InChi Key: KLBQZWRITKRQQV-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3

SMILES Code: CSC(C=C1N2CCC3N(C)CCCC3)=CC=C1SC4=C2C=CC=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 370.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lo Presti MS, Bazán PC, Strauss M, Báez AL, Rivarola HW, Paglini-Oliva PA. Trypanothione reductase inhibitors: Overview of the action of thioridazine in different stages of Chagas disease. Acta Trop. 2015 May;145:79-87. doi: 10.1016/j.actatropica.2015.02.012. Epub 2015 Feb 27. Review. PubMed PMID: 25733492.

2: Amaral L, Molnar J. Mechanisms by which thioridazine in combination with antibiotics cures extensively drug-resistant infections of pulmonary tuberculosis. In Vivo. 2014 Mar-Apr;28(2):267-71. Review. PubMed PMID: 24632985.

3: Amaral L, Martins A, Spengler G, Hunyadi A, Molnar J. The mechanism by which the phenothiazine thioridazine contributes to cure problematic drug-resistant forms of pulmonary tuberculosis: recent patents for "new use". Recent Pat Antiinfect Drug Discov. 2013 Dec;8(3):206-12. Review. PubMed PMID: 24320229.

4: Amaral L. Thioridazine: an old neuroleptic effective against totally drug resistant tuberculosis. Acta Med Port. 2012 Mar-Apr;25(2):118-21. Epub 2012 Jun 25. Review. PubMed PMID: 22985923.

5: Amaral L, Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents. 2012 May;39(5):376-80. doi: 10.1016/j.ijantimicag.2012.01.012. Epub 2012 Mar 23. Review. PubMed PMID: 22445204.

6: Amaral L, Molnar J. Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine. In Vivo. 2012 Mar-Apr;26(2):231-6. Review. PubMed PMID: 22351663.

7: Boeree MJ. Global clinical trials for the treatment of TB with thioridazine. Recent Pat Antiinfect Drug Discov. 2011 May;6(2):99-103. Review. PubMed PMID: 21548879.

8: Sohaskey C. Latent tuberculosis: is there a role for thioridazine? Recent Pat Antiinfect Drug Discov. 2011 May;6(2):139-46. Review. PubMed PMID: 21548878.

9: Thanacoody RH. Thioridazine: the good and the bad. Recent Pat Antiinfect Drug Discov. 2011 May;6(2):92-8. Review. PubMed PMID: 21548877.

10: Amaral L, Viveiros M, Molnar J, Kristiansen JE. Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of "new uses". Recent Pat Antiinfect Drug Discov. 2011 May;6(2):84-7. Review. PubMed PMID: 21548876.

11: Dutta NK, Mazumdar K, Dastidar SG, Karakousis PC, Amaral L. New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective. Recent Pat Antiinfect Drug Discov. 2011 May;6(2):128-38. Review. PubMed PMID: 21517741.

12: Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents. 2010 Jun;35(6):524-6. doi: 10.1016/j.ijantimicag.2009.12.019. Epub 2010 Feb 25. Review. PubMed PMID: 20188526.

13: Amaral L, Martins M, Viveiros M, Molnar J, Kristiansen JE. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Curr Drug Targets. 2008 Sep;9(9):816-9. Review. PubMed PMID: 18781927.

14: Thioridazine. Tuberculosis (Edinb). 2008 Mar;88(2):164-7. doi: 10.1016/S1472-9792(08)70028-3. Review. PubMed PMID: 18486062.

15: Thanacoody HK. Thioridazine: resurrection as an antimicrobial agent? Br J Clin Pharmacol. 2007 Nov;64(5):566-74. Epub 2007 Aug 31. Review. PubMed PMID: 17764469; PubMed Central PMCID: PMC2203271.

16: Fenton M, Rathbone J, Reilly J, Sultana A. Thioridazine for schizophrenia. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001944. Review. PubMed PMID: 17636691.

17: Menkes DB, Knight JC. Cardiotoxicity and prescription of thioridazine in New Zealand. Aust N Z J Psychiatry. 2002 Aug;36(4):492-8. Review. PubMed PMID: 12169148.

18: Davies SJ, Cooke LB, Moore AG, Potokar J. Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs. BMJ. 2002 Jun 22;324(7352):1519-21. Review. PubMed PMID: 12077046; PubMed Central PMCID: PMC1123452.

19: Kirchner V, Kelly CA, Harvey RJ. Thioridazine for dementia. Cochrane Database Syst Rev. 2001;(3):CD000464. Review. PubMed PMID: 11686961.

20: Amaral L, Kristiansen JE, Viveiros M, Atouguia J. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J Antimicrob Chemother. 2001 May;47(5):505-11. Review. PubMed PMID: 11328759.